QuantumBit and Biodyne Expand Neurotherapy Procedures.

Business Wire; 9/3/2004

HOUSTON -- QuantumBit Induction Technology Inc. has engaged Biodyne in the development and implementation of its clinical neurotherapy services.

The initial focus for these therapies is the treatment of Attention Deficit Disorder (ADD), thus providing an alternate to treatment with psycho-stimulants such as Ritalin.

A quote from a recent scientific animal study points to the potential negative effects of the extensive use of the psycho-stimulant, Ritalin, to treat attention deficit disorder (ADD) in our children.

" . . . in some brain regions, repeated exposure to psychomotor-stimulant drugs limits the ability of later experience to produce this form of synaptic plasticity . . . (Amphetamine or cocaine limits the ability of later experience to promote structural plasticity in the neocortex and nucleus accumbens, B Kolb, G Gorny, Y Li, A Samaha, and T Robinson, Proc Natl Acad Sci U S A. 2003 September 2; 100 (18): 10523-10528)

Recent advances in non-invasive neurotherapies offer an excellent alternative to the wide-spread use of traditional drug therapies while avoiding many negative side-effects. Other areas of successful neurotherapeutic application include addiction, learning disabilities, depression, anxiety and sleep disorders, to name a few.

In addition, neurotherapy has been shown to significantly increase memory and cognitive function. A recent pilot study has even indicated the effectiveness of neurotherapy in slowing the neurocognitive degeneration associated with early-stage Alzheimer's disease thus potentially delaying the need and costs associated with assisted-care for these patients.